7:00 am
Registration / Continental Breakfast / Visit Exhibits

8:00 am
Welcome
Ted Parran, MD, OHSAM president

Introductions & Moderator
Gregory Boehm, MD, FASAM, OHSAM education committee chair          

8:10 am
Treatment for Novel Psychoactive Substances
Michael Weaver, MD, DFASAM, University of Texas Health Science Center at Houston

Patterns of drug use are constantly changing, particularly regarding new psychoactive substances, which can be challenging to identify and treat effectively, especially serious medical and psychiatric complications. This is important for practitioners, as new designer drugs have resulted in multiple deaths, as well as other significant health consequences to users. This session will educate practitioners about several new drug use trends and their health consequences. By attending you should be able to identify emerging psychoactive substances, including kratom, phenibut, synthetic cannabinoids, and others, and discuss treatment of medical and psychiatric complications resulting from use of emerging substances of abuse.

8:40 am
Methamphetamine Addiction Treatment
Michael Weaver, MD, DFASAM, University of Texas Health Science Center at Houston

Methamphetamine use is highly prevalent across the U.S. Use of methamphetamine can lead to serious medical and mental health complications, so people with methamphetamine use disorder are likely to come into contact with the health care system. Recognition of methamphetamine use and awareness of effective treatments in important for healthcare providers. By attending you should be able to discuss problems resulting from use of methamphetamine and compare different behavioral and medication treatments for stimulant use disorder.

9:10 am
Perinatal Cannabis
Lulu Zhao, MD, FACOG, FASAM, Director of RISE-Moms, University Hospitals Cleveland Medical Center

Cannabis use in America has increased significantly over the past decade, bolstered by increased access and normalization. Ohio is now poised to become the 24th state to legalize adult use of cannabis for recreational purposes. Healthcare providers should expect that pregnant and postpartum women who use cannabis will desire more nuanced and educated conversations regarding their use in this evolving medico-legal landscape. This discussion will review the history of cannabis in America, the most up to date evidence regarding cannabis use in the perinatal period, and social justice aspects of cannabis use during pregnancy and postpartum.

9:40 am
Special Considerations for Treating SUDs in Pregnant and Breastfeeding Patients Layne
A. Gritti, DO, Sweetgrass Psychiatry

For providers who do not regularly manage patients who are pregnant and breastfeeding, these patients can be intimidating due to the special considerations to consider when treating them. This session will present a way to think about approaching these patients and give them the tools to find the answers they need. By attending you should be able to complete a Risk-Risk analysis for a number of medications we commonly use in SUD treatment, and evaluate PLLR labeling.

10:10 am
Break / Visit Exhibits and Scientific Posters

11:00 am
Contraception Essentials for the Addiction Specialist
Zevidah Vickery, MD, MSCI, MetroHealth Medical Center, Case Western Reserve University

As much as 50% of American pregnancies are not planned; evidence shows that women with substance use and use disorders experience mistimed and unintended pregnancy at even higher rates. Pregnancies affected by substance use are at greater risk of poor outcomes such as miscarriage, preterm labor, abruptio placentae, fetal growth restriction and neonatal abstinence syndrome. As with any chronic disease, optimization of maternal health before conception is recommended for pregnancy-capable people with SUD. The addiction specialist, with their trust-worthy non-judgmental care and frequent visits, is uniquely situated to assist these patients with meeting their lifetime reproductive goals. By attending you should be able to describe the unmet need for sexual and reproductive healthcare among SUD patients and develop strategies on ways to meet this need among your own patient panel.

11:30 am
Neonatal Abstinence Syndrome
William Goldman, DO, FABP, Diplomate ABPM, Medical Director, Akron Children’s Hospital Addiction Services

There is an increasing number of babies are born to mothers with opioid-use disorder, which results in drug withdrawal. By attending you should be able to define neonatal abstinence syndrome (NAS), recognize the infant presenting with signs of NAS, develop a management plan and provide guidance regarding home-care and follow up.

11:45 am
Women & Children’s Health Panel Discussion
Drs. Zhao, Gritti, Vickery and Goldman – moderated by Dr. Boehm

12:00 pm
Lunch / Visit Exhibits and Scientific Posters

12:45 pm
Ohio’s Initiatives to Combat the Opioid Epidemic & Budget and Priorities to Prevent and Address Substance Use Disorders
Lori Criss, Director, Ohio Department of Mental Health & Addiction Services

1:15 pm
Ohio Office-based Opioid Treatment (OBOT) Rules Update
James Roach, Esq., Enforcement Attorney, State Medical Board of Ohio

1:30 pm

The Changing Landscape of Addictions: Gambling/Gaming Disorder, Treatment, and Recovery
Heather A. Chapman, PhD, ICGC II, BACC, Assistant Chief Psychology Service, Director Gambling Treatment Program, Deputy Director Louis Stokes Cleveland Veterans Addiction Recovery Program

Addictions has always been impacted by accessibility factors. In recent years internet, social media, and mobile technology have created the perfect platform for unprecedented access, that then has significant psychosocial consequences. This presentation will discuss the changing landscape of addictions, highlighting gaming/gambling as process addictions become more prevalent due to these availability factors. Elements of neurobiology will be reviewed, as will treatment considerations. By attending you should be able to list the changes in the concept of what constitutes an addiction and identify strategies for gaming/gambling addictive behavior.

2:00 pm
Addressing Barriers & Disparities in Addiction Treatment
Kathleen Alto, PhD, Licensed Clinical Psychologist, MetroHealth

According to SAMHSA 2021 National Survey of Drug Use and Health, 2.6% of people aged 12 and over meet criteria for a substance use disorder in the last year, but only 1.5% of people received treatment in the last year. Certain populations, including racial and ethnic minorities, sexual and gender minorities, and the disabled face experience marked disparities in access to quality addiction treatment. To achieve health equity, it is critical to identify and address unique barriers faced by this population. By attending you should be able to describe disparities in addiction treatment for marginalized populations, including social, cultural, and political influences, name common barriers to substance use disorder treatment for marginalized populations, and identify one barrier in your institution for you to target for potential change.

3:00 pm
Screening, Treatment and Pharmacological Clinical Considerations for HCV in Persons with Substance Use
James Hanje, MD, FAASLDO, Ohio Gastroenterology Group and Co-Medical Director for the Comprehensive Liver Center at Ohio Health Kenneth Barga, PharmD, BCPS, BCACP, Ambulatory Hepatology Pharmacist, OhioHealth Comprehensive Liver Program

People who use drugs have a high prevalence of hepatitis C virus (HCV) and other infectious diseases along with significant morbidity associated with drug use, especially when injection drug use is involved. By attending you should be able to identify viral and bacterial infections associated with injection drug use, explain the differences between the disease expression and treatment of Hepatitis A and B, and develop actions you could take to integrate HIV and HCV education into your opioid safety efforts.

3:45 pm
HCV Panel Discussion

4:00 pm
Poster Awards / Business Meeting / Adjourn